Anavex Life Sciences Corp.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer, which have significant unmet medical needs. ANAVEX 2-73, the Company’s orally available drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties. A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®). The combined therapeutics, referred to as “ANAVEX PLUS,” produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. ANAVEX PLUS is believed to be a compelling commercial opportunity. The clinical trial risk is lower because donepezil (Aricept®) is already on the market, with global sales of $4-billion annually. Donepezil (Aricept®) is now generic and a patent application has been filed for ANAVEX PLUS which, if granted, would provide protection until 2033.